/DRUG
DRUG Stock - Bright Minds Biosciences Inc.
Healthcare|BiotechnologyNASDAQ
$84.00+6.49%
+$5.12 (+6.49%) • Dec 19
71
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).46
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-1.8%upside
Target: $82.49
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for DRUG
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$83.16 – $84.84
TARGET (TP)$82.50
STOP LOSS$77.28
RISK/REWARD1:-0.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.53
52W High$97.75
52W Low$23.18
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-2,616,636 | $-7,199,763 | $-14,732,012 | $-8,623,119 | $-474,926 |
| Net Income | $-2,801,946 | $-7,372,225 | $-14,964,940 | $-8,650,763 | $-480,377 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.65 | $-1.98 | $-6.15 | $-4.74 | $-0.38 |
Company Overview
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
5 Bullish0 Neutral/Bearish
Price Targets
$81
Average Target
↓ 3.6% Downside
Now
$72
Low
$81
Average
$93
High
Based on 5 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 8th 2025 | BTIG Research | Initiation | Buy | $72 |
| May 13th 2025 | TD Cowen | Initiation | Buy | - |
| May 7th 2025 | Chardan Capital Markets | Initiation | Buy | $80 |
| January 23rd 2025 | Piper Sandler | Initiation | Overweight | $93 |
| January 10th 2025 | Cantor Fitzgerald | Initiation | Overweight | - |
| January 10th 2025 | H.C. Wainwright | Initiation | Buy | $85 |
| November 26th 2024 | Robert W. Baird | Initiation | Outperform | $75 |
Earnings History & Surprises
DRUGBeat Rate
100%
Last 3 quarters
Avg Surprise
+62.5%
EPS vs Estimate
Beats / Misses
3/0
Last 12 quarters
Latest EPS
$-0.53
Q3 2025
EPS Surprise History
Q3 23
No data
Q4 23
No data
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
+72.9%
$-0.12vs$-0.44
Q1 25
+104.3%
$0.01vs$-0.23
Q3 25
+10.2%
$-0.53vs$-0.59
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Aug 14, 2025 | $-0.59 | $-0.53 | +10.2% | ✓ BEAT |
Q1 2025 | Feb 13, 2025 | $-0.23 | $0.01 | +104.3% | ✓ BEAT |
Q4 2024 | Dec 30, 2024 | $-0.44 | $-0.12 | +72.9% | ✓ BEAT |
Q3 2024 | Aug 14, 2024 | — | $0.04 | — | — |
Q2 2024 | May 15, 2024 | — | $-0.10 | — | — |
Q1 2024 | Feb 12, 2024 | — | $-0.32 | — | — |
Q4 2023 | Dec 29, 2023 | — | $-0.30 | — | — |
Q3 2023 | Aug 14, 2023 | — | $-0.29 | — | — |
Q2 2023 | May 15, 2023 | — | $-0.08 | — | — |
Q1 2023 | Feb 7, 2023 | — | $-0.10 | — | — |
Q4 2022 | Dec 29, 2022 | — | $-0.15 | — | — |
Q3 2022 | Aug 12, 2022 | — | $-0.87 | — | — |
Q2 2022 | May 16, 2022 | — | $-1.51 | — | — |
Q1 2022 | Feb 14, 2022 | — | $-1.61 | — | — |
Q4 2021 | Dec 29, 2021 | — | $-0.24 | — | — |
Q3 2021 | Jul 17, 2021 | — | $-1.26 | — | — |
Q2 2021 | Jun 17, 2021 | — | $-0.46 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.91 | — | — |
Q3 2020 | Sep 30, 2020 | — | $-0.25 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.03 | — | — |
Latest News
'Psychedelics Show Promise As An 'Entirely New Type Of Anti-Inflammatory Treatment,' Research Suggests' - Marijuana Moment
📈 PositiveBenzinga•Oct 13, 2025, 05:28 PM•Also: , ,
'New York Lawmakers Hold Hearing Psilocybin's Medical Benefits Amid Broader Debate Over Psychedelics Reform' - Marijuana Moment
➖ NeutralBenzinga•Oct 2, 2025, 03:03 PM•Also: , ,
HC Wainwright & Co. Reiterates Buy on Bright Minds Biosciences, Maintains $85 Price Target
📈 PositiveBenzinga•Sep 15, 2025, 11:10 AM
'Massachusetts Lawmakers Approve Bill To Create Psychedelic Therapy Pilot Program' - Marijuana Moment
📈 PositiveBenzinga•Sep 12, 2025, 04:30 PM•Also: , ,
BTIG Initiates Coverage On Bright Minds Biosciences with Buy Rating, Announces Price Target of $72
📈 PositiveBenzinga•Sep 8, 2025, 10:10 AM
Reported Earlier, Bright Minds Biosciences Enters Equity Distribution Agreement For At-The-Market Offering Of Up To $100M Common Shares
➖ NeutralBenzinga•Sep 5, 2025, 06:56 AM
Bright Minds Biosciences Announced Preclinical Results For BMB‑201.
📈 PositiveBenzinga•Sep 4, 2025, 12:40 PM
'Military To Start Testing Service Members For The Psychedelic Psilocin, Memo Shows' - Marijuana Moment
➖ NeutralBenzinga•Aug 28, 2025, 06:16 PM•Also: , ,
'GOP Senator Is 'Confident' Psychedelics Access Will Expand Under Trump, Saying Many Veterans Speak To Him About The Benefits' - Marijuana Moment
📈 PositiveBenzinga•Aug 22, 2025, 07:53 PM•Also: , ,
HC Wainwright & Co. Reiterates Buy on Bright Minds Biosciences, Maintains $85 Price Target
📈 PositiveBenzinga•Aug 19, 2025, 05:55 PM
Frequently Asked Questions about DRUG
What is DRUG's current stock price?
Bright Minds Biosciences Inc. (DRUG) is currently trading at $84.00 per share. The stock has moved +6.49% today.
What is the analyst price target for DRUG?
The average analyst price target for DRUG is $82.50, based on 1 analyst.
What sector is Bright Minds Biosciences Inc. in?
Bright Minds Biosciences Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is DRUG's market cap?
Bright Minds Biosciences Inc. has a market capitalization of $0.60 billion, making it a small-cap company.
Does DRUG pay dividends?
No, Bright Minds Biosciences Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALT
Altimmune, Inc.
$3.90
Mkt Cap: $0.3B
ANNX
Annexon, Inc.
$5.17
Mkt Cap: $0.6B
AURA
Aura Biosciences, Inc.
$5.86
Mkt Cap: $0.4B
DMAC
DiaMedica Therapeutics Inc.
$8.48
Mkt Cap: $0.4B
DSGN
Design Therapeutics, Inc.
$9.68
Mkt Cap: $0.6B
ENGN
enGene Holdings Inc.
$8.69
Mkt Cap: $0.4B
GALT
Galectin Therapeutics Inc.
$4.38
Mkt Cap: $0.3B
IMAB
I-Mab
$3.95
Mkt Cap: $0.3B
KRRO
Korro Bio, Inc.
$7.88
Mkt Cap: $0.1B
LBRX
LB Pharmaceuticals Inc Common Stock
$21.07
Mkt Cap: $0.5B
Explore stocks similar to DRUG for comparison